|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
ProMisE was applied to a retrospective cohort of women with ECs <50 yo at diagnosis, and associations between the four ProMisE molecular subtypes (MMR deficient (MMRd), POLE mutated (POLE), p53 wild type (p53wt), and p53 abnormal (p53abn)) and clinicopathological parameters, including outcomes, were assessed.
|
30922603 |
2019 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
For endometrial cancer, four molecular subgroups have undergone extensive studies in recent years: POLE ultramutated (POLEmut), mismatch repair-deficient (MMRd), p53 mutant (p53abn) and those EC lacking any of these alterations, referred to as NSMP (non-specific molecular profile).
|
31846532 |
2020 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Phospho-p53 seems to be the functional p53 protein and was examined for the first time in endometrial cancer.
|
22210468 |
2012 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We suggest that molecular alterations in p53 and the mTORC1 pathway play different roles in the initiation of the different endometrial cancer subtypes, but that combined p53 inactivation and mTORC1 pathway activation are unifying pathogenic features among histologically diverse subtypes of late stage aggressive endometrial tumours.
|
22678923 |
2012 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We investigated 46 paired primary human endometrial carcinomas and normal tissues to assess the frequency of loss of heterozygosity (LOH) in Rb and 20 tumor pairs to detect the frequency of p53 LOH.
|
12461615 |
2002 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison.
|
9421075 |
1997 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In this article, the prevalence of allelic loss at the TP53 locus in primary human endometrial carcinomas (ECs) is discussed.
|
20453538 |
2010 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that p53 mutations occur in human endometrial carcinoma, although relatively infrequently, and that loss of the normal p53 allele does not necessarily occur with point mutation of the p53 gene in this tumor type.
|
1497800 |
1992 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A high frequency of allelic losses corresponding to the 17p13.3 region that contained the p53 gene sequence was also noted in human endometrial carcinoma.
|
8473053 |
1993 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Polymorphic frequency of p53 codon 72 was also various among the cells, however, the Pro allele was found in only 1 of 6 kidney, 14 cervical and 4 endometrial carcinoma cell lines.
|
15147044 |
2003 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Disruptions at p16INK4A and/or cdk4/cyclin D1 concomitantly occurring with TP53 LOH may participate in the development of a subset of endometrioid-type ECs.
|
16293976 |
2005 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We conclude that TP53 protein analysis by LIA provides an incomplete correlation to mutation status and cannot substitute for mutation analysis in assessment of prognosis in endometrial carcinoma.
|
12144684 |
2002 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
For 276 cases, we obtained tissue blocks of endometrial cancer to review the diagnosis, and used immunohistochemistry to examine hormone-receptor status and overexpression of p53.
|
11036892 |
2000 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The authors evaluated the TP53 and KRAS2 genes for mutations in sporadic endometrial carcinomas with microsatellite instability (MSI) and matched MSI negative controls to determine whether defective DNA mismatch repair impacts the patterns of mutations in two genes known to be involved in endometrial tumorigenesis.
|
9921983 |
1999 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Conversely, alterations in the PTEN and TP53 genes seem to define distinct subgroups of endometrial carcinoma, the former associated with diploidy and MSI, the latter with macroscopic chromosomal instability.
|
12015762 |
2002 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Absence of p53 expression appears to be associated with concurrent endometrial carcinoma.
|
10785470 |
2000 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III.
|
30636711 |
2019 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer.
|
12055672 |
2002 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The p53 gene (bases 166-1143 from start codon) with the codon 72 polymorphism, inserted into the pIRES-hrGFP II plasmid with or without upstream ERE, were transfected into HHUA endometrial cancer cells expressing the estrogen receptor.
|
21790217 |
2011 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Most endometrial carcinoma with p53 overexpression and/or mutation had a relatively poor prognosis and showed no reactivities of ER or PR.
|
10101596 |
1999 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Finally, a subset of TP53-mutant ECs (22%) was found to harbor frameshift or nonsense mutations.
|
26556035 |
2016 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These data support the hypothesis that differences in the frequency of alteration of the p53 tumor suppressor gene contribute to the racial disparity in endometrial cancer survival.
|
9215213 |
1997 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that p53 codon 72 polymorphism is not associated with increased risk of endometrial cancer, especially in Caucasians and Asians.
|
22277327 |
2012 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer.
|
23729685 |
2013 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
UBE2C is upregulated by estrogen and promotes epithelial-mesenchymal transition via p53 in endometrial cancer.
|
31662448 |
2020 |